Biotechnology and the Future of Medicine

The 2020 HMS Annual Bioethics Conference will be held from March 9-10, 2020.

Sign-up here for conference schedule and registration information.
 

About the Conference:

The 2020 Annual Bioethics Conference will explore the potential of biotechnology to drive and shape the future of clinical care and research.

The practice of medicine over the course of the last 50 years has changed dramatically. Novel technological developments will continue to generate new discoveries, therapies, and patient outcomes. Recent advances in intertwined areas, such as stem cell-based bioengineering, organoid technology, low-cost personal genome sequencing, machine learning, and human genome editing have the potential to create more effective, personalized medical treatments. But as we progress toward this biotechnologically-driven medical future, we must consider how ethical values can shape these advancements and vice versa. This conference will examine how ethics interacts with biotechnology in medicine, and consider multiple approaches to how we might ensure that biotechnology continues to evolve ethically.

The Harvard Medical School Annual Bioethics Conference convenes leaders in the field to explore ethical questions and concerns in healthcare. Held each April, this conference facilitates conversations among experts, and supports members of ethics committees, health care professionals, bioethicists, administrators, attorneys and others who are interested in addressing ethical issues.

Registration is $50 for two days of programing.


PAST ANNUAL BIOETHICS CONFERENCES
2019: Controlling Death: The policies, practices, and ethics of choosing when we die
2018: Defining Death: Organ transplantation and the 50-year legacy of the Harvard report on "brain death"
2017: The Ethics of "Making Babies"
2016: Social Justice and Ethics Committees in Health Care



The Harvard Annual Bioethics Conference is hosted and organized by the Center for Bioethics at Harvard Medical School and co-sponsored by the Hastings Center and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School with support from the Oswald DeN. Cammann Fund at Harvard University.

Endorsed by the American Society for Bioethics and Humanities.